Financial Performance - Total revenue for the first quarter was $115.9 million, representing a 15% year-over-year increase[8] - Adjusted EBITDA for the quarter was $20.8 million, compared to $4.1 million in the same period last year[8] - Net loss for the quarter was $3.9 million, significantly improved from a net loss of $19.7 million in the prior year[8] - Total revenues for the three months ended April 30, 2025, were $115,936,000, a 14.5% increase from $101,217,000 in the same period of 2024[20] - Adjusted EBITDA for the three months ended April 30, 2025, was $20,816,000, compared to $4,093,000 in the same period of 2024, indicating a substantial increase[32] - Net loss for the three months ended April 30, 2025, was $3,914,000, significantly improved from a net loss of $19,722,000 in the same period of 2024[22] - The company reported a comprehensive loss of $3,479,000 for the three months ended April 30, 2025, compared to a comprehensive loss of $19,721,000 in the same period of 2024[22] Client Metrics - Average number of healthcare services clients (AHSCs) was 4,411, up 9% year-over-year[8] - Average number of healthcare services clients (AHSCs) rose to 4,411 in Q1 2025 from 4,065 in Q1 2024, reflecting a growth of 8.5%[39] - The company expects to reach approximately 4,500 AHSCs in fiscal 2026, with total revenue per AHSC projected to increase from fiscal 2025[5] Revenue per Client - Total revenue per AHSC was $26,283, an increase of 6% year-over-year[8] - Total revenue per AHSC increased to $26,283 in Q1 2025 from $24,900 in Q1 2024, marking a growth of 5.5%[39] Cash Position - Cash and cash equivalents as of April 30, 2025, were $90.9 million, up $6.7 million from January 31, 2025[8] - Cash and cash equivalents at the end of the period were $90,871,000, up from $79,527,000 at the end of the same period in 2024[24] - Net cash provided by operating activities was $14,850,000 for the three months ended April 30, 2025, compared to a cash outflow of $721,000 in the same period of 2024[24] - The company had no borrowings outstanding under its credit facility as of April 30, 2025, providing additional capital flexibility for growth opportunities[6] Revenue Outlook - The company maintains its revenue outlook for fiscal 2026, expecting revenue between $472 million and $482 million[4] - Adjusted EBITDA outlook for fiscal 2026 has been updated to a range of $85 million to $90 million, up from a previous range of $78 million to $88 million[5] Payment Metrics - Patient payment volume for Q1 2025 reached $1,314 million, up from $1,166 million in Q1 2024, representing an increase of approximately 12.7%[42] - Payment facilitator volume percentage increased to 82% in Q1 2025 from 81% in Q1 2024, indicating a slight growth in the proportion of transactions processed as a payment facilitator[42] - The company views patient payment volume as a key indicator of the health of its healthcare services clients' businesses and the shift of healthcare costs to patients[42] - Payment facilitator volume is a major driver of the company's payment processing revenue, with potential for slight decline in percentage as enterprise customer penetration increases[42] Expense Management - Total expenses decreased to $119,223,000 in Q1 2025 from $120,637,000 in Q1 2024, a reduction of 1.2%[20]

The upcoming report from Phreesia (PHR) is expected to reveal quarterly loss of $0.13 per share, indicating an increase of 62.9% compared to the year-ago period. Analysts forecast revenues of $114.69 million, representing an increase of 13.3% year over year.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.Before a company announces its earnings, it is e ...

Group 1 - The stock of Phreesia (PHR) closed at $24.84, showing a 2.6% increase over the past four weeks, with a mean price target of $31.80 indicating a potential upside of 28% [1] - Analysts have set 15 short-term price targets for PHR, ranging from a low of $29 to a high of $36, with a standard deviation of $2.34, suggesting a consensus among analysts [2] - The Zacks Consensus Estimate for the current year has increased by 14.4% over the last 30 days, with three estimates moving higher and no negative revisions [11] Group 2 - There is strong agreement among analysts regarding PHR's ability to report better earnings than previously predicted, which supports the expectation of an upside [4][10] - PHR holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating a strong potential for near-term upside [12] - While price targets can be misleading, the direction implied by the consensus price target for PHR appears to be a useful guide for potential price movement [9][12]

Group 1 - Phreesia (NYSE: PHR) continues to perform as expected despite recent market volatility and sell-off [1] - The company has been affected by market conditions but remains resilient [1] - Dr. Duru, a veteran in financial markets, provides unique perspectives on trading and investing through his blog [1] Group 2 - The blog covers various financial instruments including stocks, options, currencies, and Bitcoin [1] - It utilizes both technical and fundamental analysis for short-term and long-term strategies [1] - Dr. Duru has extensive academic and professional experience in engineering, operations research, and data analytics [1]

Market Overview - The current addressable market is approximately $10.0 billion, derived from $6.3 billion in subscription services, $2.3 billion in consumer-related transaction fees, and $1.9 billion in network solutions revenue[31]. - The company serves approximately 50,000 unique healthcare services clients in the ambulatory and hospital markets[31]. - The company facilitated patient visits for over 4,300 healthcare services clients across all 50 states in fiscal 2025[24]. Technology Solutions - The company offers a comprehensive range of technology solutions, including patient registration, appointment scheduling, and payment processing, aimed at improving operational efficiency[26]. - The company’s technology solutions are customizable and scalable to any size healthcare service organization[26]. - The company integrates its technology into over 4,300 healthcare services clients' PM and EHR systems, enhancing operational workflows[12]. - The company’s payment processing features are designed to operate seamlessly within client workflows, enhancing revenue cycle solutions[12]. - The company’s technology innovations include enhancements to user interface, improving user experience and satisfaction[12]. Patient Engagement and Outcomes - The company aims to activate and engage patients in their healthcare journey, resulting in improved health outcomes[35]. - The company’s solutions have demonstrated increased rates of preventive care and vaccinations through effective patient communication[24]. - The Patient Activation Measure (PAM) will be included in the Centers for Medicare and Medicaid Services' Merit-based Incentive Payments System starting in 2024, potentially impacting client performance metrics[38]. Revenue Cycle Solutions - The company offers a comprehensive suite of revenue cycle solutions that improve key metrics, including time-of-service collections and patient convenience with online payments[49]. - The company’s revenue cycle solutions help maximize timely collection of patient payments through insurance verification and point-of-sale applications[34]. - Flexible patient payment options have led to an increase in time-of-service collections for the majority of healthcare services clients, enhancing cash flow and profitability[38]. - The company’s solutions help healthcare services clients capture the right clinical information, aligning with quality reporting initiatives and reducing errors in patient data collection[38]. Client Relationships and Growth - The company plans to expand its client base in the U.S. healthcare industry, which is large and underserved, by utilizing its direct sales force to win new clients[40]. - There is a significant opportunity to deepen relationships with existing healthcare services clients by increasing the number of subscriptions and add-on applications purchased[41]. - The company intends to continue innovating and enhancing its solutions to address key challenges in healthcare, driving incremental revenue from existing clients[42]. Compliance and Security - The company is subject to extensive federal and state laws regarding privacy and security, including HIPAA and the California Consumer Privacy Act[61]. - The company has industry certifications including HITRUST and PCI-DSS Level 1 Service Provider, demonstrating commitment to data security standards[53]. - The company is subject to various federal and state laws regarding privacy, data protection, and information security, which may increase compliance costs and legal risks[73]. - The company’s subsidiary, Insignia, is a federal government contractor and must comply with the Federal Acquisition Regulation (FAR) and related requirements[76]. Financial Overview - The company’s cash and cash equivalents primarily consist of money market funds and cash on deposit, with a focus on preserving principal while maximizing income[382]. - As of January 31, 2025, the company had no debt outstanding under the Capital One Credit Facility[383]. - For the fiscal year ended January 31, 2025, approximately 85% of the company's expenses were denominated in U.S. Dollars[384]. - Foreign currency losses from the re-measurement of monetary account balances amounted to $0.4 million for the year ended January 31, 2025[385]. - A 1% increase or decrease in foreign exchange rates between the Canadian Dollar, Indian Rupee, and U.S. Dollar is not expected to have a material effect on the company's results of operations or financial condition[386]. Employee and Workplace Culture - As of January 31, 2025, the company had 2,082 full-time employees, with 817 in the United States and 1,265 internationally[83]. - The company was recognized as one of the "Best Places to Work in Healthcare" for the eighth time and named to the list of "The Top 100 Software Companies of 2024" by the Software Report[84]. - The company has operated as a fully remote organization since 2020, allowing access to a broader talent pool[87]. - The company has a commitment to gender equality and inclusive workplace practices, including pathways to leadership for women and pay equity[86]. - The company has not experienced any work stoppages and maintains a good relationship with its employees[83]. Strategic Initiatives - Strategic investments, partnerships, and acquisitions are being pursued to enhance the company's ability to activate patients in their care and expand its suite of solutions[43]. - The business model focuses on developing new, value-added applications that increase revenue and enhance client unit economics, with expectations of improving net income and margins over time[45]. - The company’s sales cycles typically range from three to six months, with most contracts structured as annual, auto-renewing agreements[56]. - The company’s marketing team focuses on educating potential clients about the value of its solutions, which positively impact health outcomes[57]. - The company’s client services team is organized by market specialization, ensuring deep expertise and efficient onboarding for healthcare services clients[64]. Risk Management - The company is exposed to market risks, including interest rate and foreign exchange risks, but does not expect significant impact from a 100 basis point change in interest rates[382]. - In February 2025, the company entered into foreign currency forward contracts to hedge against foreign currency exchange risk related to Canadian Dollar payroll payments[386]. - The foreign currency forward contracts are expected to limit the company's exposure to foreign currency exchange risk associated with forecasted Canadian Dollar payroll payments[387]. - The company emphasizes the importance of protecting its intellectual property through trademarks, trade secrets, and contractual rights[81].

Phreesia (PHR) Q4 2025 Earnings Call March 12, 2025 11:41 PM ET Company Participants Balaji Gandhi - CFOChaim Indig - Co-Founder, CEO & DirectorAnne Samuel - Executive DirectorJailendra Singh - Managing DirectorRyan Daniels - Group Head–Healthcare Technology and ServicesRichard Close - Managing DirectorJeff Garro - Managing DirectorScott Schoenhaus - Managing Director Conference Call Participants Jessica Tassan - Senior Equity Research AnalystRyan Macdonald - Senior AnalystDaniel Grosslight - Senior Researc ...

Financial Data and Key Metrics Changes - Q4 revenue was $109.7 million, up 15% year over year [10] - Q4 adjusted EBITDA was $16.4 million, reflecting a significant increase from the previous year [10] - Q4 average healthcare services clients reached $4,341, an increase of $104 from the prior quarter and $379 from the prior year [10] - Q4 total revenue per AhSE was $25,266, up 5% year over year [10] - Q4 operating cash flow was positive at $16.3 million, up $19.3 million year over year [10] - Q4 free cash flow was positive at $9.2 million, up $20.1 million year over year [10] - Cash position improved to $84.2 million as of January 31, up $2.5 million from October 31, 2024 [11] Business Line Data and Key Metrics Changes - The Appresia platform was used in approximately 14% of patient visits across the United States, equating to around 170 million sites [9] - Strong growth was noted in network solutions, with expectations for similar market conditions in 2026 as in 2025 [18][19] Market Data and Key Metrics Changes - The company is monitoring macroeconomic factors closely, including consumer confidence and Medicaid changes, but has not seen significant impacts on business as of now [66][68] Company Strategy and Development Direction - The company aims to continue generating positive free cash flow while investing in long-term profitable revenue growth [11] - The revenue outlook for fiscal year 2026 is maintained at a range of $472 million to $482 million, with adjusted EBITDA expected between $78 million and $88 million [12] - The company is focused on leveraging AI and automation to improve productivity and drive business growth [32][34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in maintaining growth despite potential macroeconomic challenges, emphasizing a strong operational foundation [66][70] - The company is committed to capital allocation strategies that prioritize durable and profitable growth, considering both organic and inorganic opportunities [70][72] Other Important Information - The company has not made any acquisitions in fiscal year 2025, but previous acquisitions are contributing to growth [75] - The company is excited about the rollout of new products that enhance patient engagement and medication adherence [8][49] Q&A Session Summary Question: What is the potential for gross margin expansion? - Management indicated that mix is a significant driver of gross margin, with expectations for higher growth in certain revenue lines contributing to expansion [16][18] Question: How are market conditions expected to change in 2026? - Management expects market conditions in 2026 to be similar to those in 2025 [19] Question: Can you explain the postscript engagement product? - The product operates on an impression-based model, leveraging data to remind patients about prescriptions [24][25] Question: What impact did the calendar have on revenue per AhSE? - Management noted that calendar factors, including holidays and weather, significantly impacted Q4 performance [30] Question: What progress has been made in leveraging AI? - Management reported positive real-time impacts from AI applications, particularly in forecasting and productivity improvements [34] Question: How is the company positioned in the competitive landscape? - Management noted improved close rates and a beneficial position as a market leader amidst new entrants [42] Question: What is the strategy for capital deployment in 2026? - The company will continue to prioritize capital allocation for durable growth, considering both organic and inorganic opportunities [70][72]

Financial Performance - Total revenue for Q4 fiscal 2025 was $109.7 million, representing a 15% year-over-year increase[7] - Fiscal 2025 total revenue reached $419.8 million, an 18% increase year-over-year[7] - Total revenues for the three months ended January 31, 2025, increased to $109.681 million, up 15.5% from $95.005 million in the same period of 2024[22] - Subscription and related services revenue rose to $51.793 million, a 13.5% increase from $45.653 million year-over-year[22] - Payment processing fees grew to $24.676 million, reflecting a 5% increase compared to $23.508 million in the prior year[22] Profitability Metrics - Adjusted EBITDA for Q4 was $16.4 million, compared to negative $3.5 million in the same period last year[7] - Adjusted EBITDA for the three months ended January 31, 2025, was $16,373, compared to a loss of $3,461 for the same period in 2024[34] - Free cash flow for Q4 was $9.2 million, compared to negative $10.9 million in the same period last year[7] - Free cash flow for the fiscal year ended January 31, 2025, was $8,292, a significant improvement from a negative $57,475 in the previous year[37] - The company reported a net loss of $58.5 million for fiscal 2025, improved from a net loss of $136.9 million in fiscal 2024[7] - Net loss for the fiscal year ended January 31, 2025, was $(58.527) million, a significant reduction from $(136.885) million in the previous fiscal year[22] - The company reported a net loss of $6,390 for the three months ended January 31, 2025, compared to a net loss of $30,646 for the same period in 2024[34] Client Metrics - Average number of healthcare services clients (AHSCs) was 4,341 in Q4, up 10% year-over-year[7] - The company anticipates AHSCs to reach approximately 4,500 in fiscal 2026[9] - The average number of healthcare services clients (AHSCs) increased to 4,341 in Q1 2025 from 3,962 in Q1 2024, representing a growth of 9.6%[40] - Total revenue per AHSC for the fiscal year ended January 31, 2025, was $99,884, up from $98,944 in the previous year, indicating a growth of 0.9%[40] Cash and Liquidity - Cash and cash equivalents as of January 31, 2025, were $84.2 million, providing sufficient flexibility for future growth[10] - Cash and cash equivalents at the end of the period were $84.220 million, slightly down from $87.520 million a year earlier[26] - The company reported a net cash provided by operating activities of $16.256 million for the three months ended January 31, 2025, compared to a net cash used of $(3.078) million in the same period of 2024[26] Future Outlook - The outlook for fiscal 2026 revenue is projected to be between $472 million and $482 million[8] - Adjusted EBITDA for fiscal 2026 is expected to range from $78 million to $88 million[9] Operating Expenses - Operating loss for the three months ended January 31, 2025, improved to $(7.612) million from $(29.578) million in the same quarter of 2024[22] - GAAP operating expenses for the three months ended January 31, 2025, totaled $93,411, down from $100,696 in the same period of 2024, a decrease of 7.8%[39] - Stock-based compensation expense for the fiscal year ended January 31, 2025, was $66,975, compared to $71,613 in 2024, a reduction of 6.2%[39] Asset and Liability Overview - Total assets increased to $388.415 million as of January 31, 2025, compared to $370.326 million in the previous year[20] - Total liabilities rose to $123.607 million, up from $118.877 million year-over-year[20] Development Costs - Capitalized internal-use software development costs for the fiscal year ended January 31, 2025, were $15,380, down from $19,291 in 2024, a decrease of 20.0%[37] Payment Volume - Patient payment volume reached $1,080 million in Q1 2025, compared to $977 million in Q1 2024, reflecting an increase of 10.5%[41] - The payment facilitator volume percentage remained stable at 82% for both Q1 2025 and Q1 2024[41]

Company Overview - Phreesia (PHR) shares increased by 5.6% to $30.01 in the last trading session, with a higher-than-average trading volume, compared to a 4.9% gain over the past four weeks [1] - The company is recognized for its leadership, as Sally Thayer, Vice President of Product Management, was named to The Software Report's list of the Top 50 Women Leaders in Software of 2024, marking the seventh consecutive year a female leader from Phreesia has received this honor [2] Financial Performance - Phreesia is expected to report a quarterly loss of $0.19 per share, reflecting a year-over-year improvement of 66.1%, with anticipated revenues of $108.91 million, up 14.6% from the same quarter last year [3] - The consensus EPS estimate for the upcoming quarter has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] Industry Context - Phreesia operates within the Zacks Medical Info Systems industry, which includes other companies like Pulmonx Corporation (LUNG), whose shares also saw a 5.3% increase to $7.38 in the last trading session, with a 4.3% return over the past month [4] - Pulmonx's consensus EPS estimate for its upcoming report has remained unchanged at -$0.43, representing a year-over-year change of -19.4% [5]

Core Viewpoint - Phreesia's stock has shown significant performance, increasing by 16.4% over the past month and reaching a 52-week high of $29.36, outperforming the broader medical sector and medical information systems industry [1][2]. Financial Performance - Phreesia has consistently exceeded earnings expectations, reporting an EPS of -$0.25 against a consensus estimate of -$0.29 in its last earnings report [2]. - For the current fiscal year, Phreesia is projected to have an EPS of -$1.10 with revenues of $419.04 million, reflecting a 56.18% change in EPS and a 17.61% change in revenues [3]. - The next fiscal year forecasts an EPS of -$0.38 and revenues of $476.77 million, indicating a year-over-year change of 66.18% in EPS and 13.78% in revenues [3]. Valuation Metrics - Despite reaching a 52-week high, the future valuation metrics of Phreesia need to be assessed to determine if the stock has become overvalued [4]. Zacks Style Scores - Phreesia has a Value Score of D, a Growth Score of A, and a Momentum Score of D, resulting in a combined VGM Score of B [6]. Zacks Rank - Phreesia holds a Zacks Rank of 2 (Buy), supported by rising earnings estimates, suggesting potential for further stock price appreciation [7].